Methotrexate
‘Aggressive therapy’ key in axial spondyloarthritis despite lack of T2T recommendation
SAN DIEGO — Although current American College of Rheumatology guidelines eschew treat-to-target for axial spondyloarthritis, “aggressive treatment” is still needed to manage the disease, noted a speaker here.
‘Negligible’ melanoma risk observed in patients treated with methotrexate
Findings from a comprehensive systematic review and meta-analysis showed a “negligible” risk for melanoma among individuals treated with methotrexate.
Pre-arthritis methotrexate use improves RA course, fails to prevent clinical arthritis
Methotrexate use at the pre-arthritis stage of symptoms and subclinical inflammation fails to prevent clinical arthritis, but does improve symptoms and MRI-detected inflammation vs. placebo, according to data published in The Lancet.
Ozoralizumab reduces RA signs, symptoms in patients who fail methotrexate
Ozoralizumab, in either the 30 mg or 80 mg formulation, significantly reduces rheumatoid arthritis signs and symptoms in patients with an inadequate response to methotrexate, according to data published in Arthritis & Rheumatology.
Olokizumab bests placebo, noninferior to adalimumab in RA with methotrexate
Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in patients with rheumatoid arthritis who were receiving methotrexate as a maintenance therapy, according to data.
Antibody response to COVID-19 booster doubles in patients who paused methotrexate
Patients who suspended methotrexate for 2 weeks after a COVID-19 booster vaccine had a “twofold” increased antibody response, compared with those who remained on the drug, according to data published in The Lancet Respiratory Medicine.
ACR: Infants exposed to TNFi in utero should receive rotavirus vaccine within 6 months
Infants who have been exposed to tumor necrosis factor inhibitors in utero should receive the rotavirus vaccine in the first 6 months of life, according to new recommendations from the American College of Rheumatology.
Denial of methotrexate prescriptions post-Roe yields ‘condemnation’
The June 24 Supreme Court decision to overturn Roe vs. Wade continues to reverberate across all of health care, including rheumatology, dermatology and cancer treatment — and in this instance all three at once.
Predictive models in rheumatoid arthritis, methotrexate use allow more personalized care
Prediction models for rheumatoid arthritis outcomes, including infection and stroke, demonstrated strong performance and may be viable as a study tool for clinical use, according to data published in Seminars in Arthritis and Rheumatism.
‘One of the few strategy trials in PsA’: CONTROL sheds light on escalation, biologic use
Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs individually, there are fewer trials examining strategies to treat patients who fail to respond to methotrexate in the first line.